

# Investigation Report on China Ambroxol Market, 2010-2019

<https://marketpublishers.com/r/IDBC9BC1F50EN.html>

Date: July 2015

Pages: 40

Price: US\$ 2,000.00 (Single User License)

ID: IDBC9BC1F50EN

## Abstracts

### Description

In recent years, respiratory disease has become the third health killer with high incidence and fatality in China. Therefore, developing respiratory drugs has become an important part of pharmaceutical research. In the case of respiratory tract infection like chronic bronchitis, large amounts of sputum will be generated which can block the respiratory tract and cause cough and gasp. Sputum can even make it difficult for people to breathe or spit especially when patients are children and old people. Therefore the application of expectorant represented by mucus regulator is quite necessary.

Through years of development, ambroxol, the third generation of expectorant, has been widely applied in the clinic. The chemical composition of ambroxol is ambroxol hydrochloride which is the active metabolite of bromhexine. First developed and registered by German scholars in the late 1970s, ambroxol was marketed by Boehringer Ingelheim (Germany) under the trade name of Mucosolvan in Germany in 1981. And it has now entered many countries in the world. Compared with the former two generations of expectorant, ambroxol can provide strong dissolution of mucus. Characterized by promoting alveolar cell's intake of phosphatidylcholine and synthesis of pulmonary surfactant, reducing airway resistance, stimulating mucous gland secretion and diluting mucus so as to improve its transport and release, ambroxol is now a main species of oral expectorant in the clinic.

In 1994, ambroxol made by Boehringer Ingelheim (Germany) entered China under the trade name of Mucosolvan, followed by Ambrohexal of HEXAL. Ambroxol develops fast after entering China, annual sales value rising from less than CNY 200 million in 2005 to

CNY 943 million in 2014 and CAGR during this period reaching 20.9%. Boehringer Ingelheim (Spain), Shenyang Xin Ma Pharmaceutical Co., Ltd, Changzhou Siyao Pharmaceuticals Co., Ltd and Boehringer Ingelheim (Shanghai) occupy the majority of the Chinese market, among which Boehringer Ingelheim (Spain) has the largest market share of about 42% for sales value in 2014.

With the degradation of environmental pollution, the incidence of respiratory diseases is expected to keep increasing, so does the market size of ambroxol in China in the next few years.

Readers can get at least the following information from this report:

market size of ambroxol in China

competitive landscape of ambroxol in Chinese market

price of ambroxol made by different enterprises in China

market outlook of ambroxol in China

The author suggests the following groups of people purchase this report:

manufacturers of drugs for respiratory system

investors/ research institutions interested in Chinese medicine market

any interest in the Chinese medicine market, please contact CRI for customized survey service

## Contents

### **1 RELATED CONCEPTS OF AMBROXOL**

- 1.1 Indication
- 1.2 Sales Status in Global Market

### **2 MARKET PROFILE OF AMBROXOL IN CHINA**

- 2.1 Patent and Approval Status of Ambroxol in China
- 2.2 Major Manufacturers
- 2.3 Market Size

### **3 SURVEY ON SALES STATUS OF AMBROXOL IN CHINA, 2010-2014**

- 3.1 Sales Value
  - 3.1.1 Overall Sales Value
  - 3.1.2 Sales Value by Regions
- 3.2 Sales Volume
  - 3.2.1 Overall Sales Volume
  - 3.2.2 Sales Volume by Regions

### **4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF AMBROXOL IN CHINA, 2010-2014**

- 4.1 Market Share by Sales Value
- 4.2 Market Share by Sales Volume

### **5 SURVEY ON DOSAGE FORMS OF AMBROXOL IN CHINA, 2010-2014**

- 5.1 Share of Different Dosage Forms by Sales Value
- 5.2 Share of Different Dosage Forms by Sales Volume

### **6 REFERENCE PRICE OF AMBROXOL IN CHINESE HOSPITALS IN 2014**

- 6.1 Boehringer Ingelheim (Shanghai) (Trade Name: Mucosolvan)
- 6.2 Yunnan Longhai Natural Phyto Pharmaceutical Co., Ltd
- 6.3 Boehringer Ingelheim (Germany) (Trade Name: Mucosolvan)
- 6.4 Boehringer Ingelheim (France) (Trade Name: Mucosolvan)

- 6.5 Boehringer Ingelheim (Spain) (Trade Name: Mucosolvan)
- 6.6 TIPR Pharmaceutical Responsible Co., Ltd (Trade Name: Yinuoshu)
- 6.7 Changzhou Siyao Pharmaceuticals Co., Ltd (Trade Name: Lansu)
- 6.8 Shenyang Xin Ma Pharmaceutical Co., Ltd (Trade Name: Kaishun)

## **7 MAJOR MANUFACTURERS OF AMBROXOL IN CHINESE MARKET, 2010-2014**

- 7.1 TIPR Pharmaceutical Responsible Co., Ltd
- 7.2 Shenyang Xin Ma Pharmaceutical Co., Ltd
- 7.3 Changzhou Siyao Pharmaceuticals Co., Ltd
- 7.4 Boehringer Ingelheim
- 7.5 Boehringer Ingelheim (Shanghai)

## **8 MARKET OUTLOOK OF AMBROXOL IN CHINA, 2015-2019**

- 8.1 Forecast of Market Size
- 8.2 Forecast of Competitive Landscape

## I would like to order

Product name: Investigation Report on China Ambroxol Market, 2010-2019

Product link: <https://marketpublishers.com/r/IDBC9BC1F50EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IDBC9BC1F50EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970